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a  b  s  t  r  a  c  t
Gastrointestinal  mucositis  induced  during  cancer  treatment  is considered  a serious  dose-
limiting  side  effect  of  chemotherapy  and/or  radiotherapy.  Frequently,  interruption  of the
cancer treatment  due  to this  pathology  leads  to  a reduction  in  cure  rates,  increase  of  treat-
ment costs  and decrease  life quality  of  the  patient.  Natural  products  such  as  Bidens  pilosa
L. (Asteraceae),  represent  a potential  alternative  for  the  treatment  of  mucositis  given  its
anti-inﬂammatory  properties.  In this  study,  B.  pilosa  glycolic  extract  was formulated  (BPF)
with poloxamer,  a mucoadhesive  copolymer,  was used  for  treatment  of  5-ﬂuorouracil  (5-
FU)-induced  mucositis  in mice.  As  expected,  animals  only  treated  with  5-FU  (200  mg/kg)
presented  marked  weight  loss,  reduction  of intestinal  villi,  crypts  and  muscular  layer,  which
was  associated  with severe  disruption  of  crypts,  edema,  inﬂammatory  inﬁltrate  and  vac-
uolization  in the  intestinal  tissue,  as compared  to  the  control  group  and  healthy  animals
only  treated  with  BPF.  On  the  other  hand,  the  treatment  of  intestinal  mucositis-bearing
mice with  BPF  (75,  100  or 125  mg/kg)  managed  to  mitigate  clinical  and  pathologic  changes,
noticeably  at  100  mg/kg.  This  dose  led to the  restoration  of  intestinal  proliferative  activity
through  increasing  Ki-67  levels;  modulated  the  expression  of  Bax, Bcl2  and  p53  apoptotic
markers  protecting  intestinal  cells from  cell  death.  Moreover,  this  treatment  regulated  lipid
peroxidation  and  inﬂammatory  inﬁltration.  No  acute  toxic  effects  were  observed  with  this
formulation.  This  work  demonstrated  that BPF was  safe  and  effective  against  5-FU-induced
intestinal  mucositis  in  mice.  Additional  studies  are  already  in progress  to further  charac-
terize  the  mechanisms  involved  in the protective  effects  of  this  technological  formulation
toward  the  development  
injury  in  patients  undergo
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1. Introduction
Gastrointestinal mucositis induced during cancer treat-
ment is considered a serious dose-limiting side effect of
chemotherapy and/or radiotherapy, since this condition
promotes severe ulceration and inﬂammation of the gas-
trointestinal tract, mainly in the small intestine [1–3].
Interruption of the cancer treatment due to mucositis usu-
ally leads to a reduction in cure rates, increase treatment
costs, decrease quality of life and, consequently worsening
prognosis of the disease [3–5].
Currently, there is no curative intervention for inﬂam-
matory mucositis induced by the cancer treatment.
Palliative measures for mucositis in the clinic includes oral
cryotherapy, soft laser application and systemic adminis-
tration of medicines, such as glucocorticoids and growth
factors [2,6–8]. Considering the high cost of some thera-
peutic procedures and the low efﬁcacy, the development
of alternative treatments, such as using natural products,
it has been considered [9].
Bidens pilosa L. (Asteraceae), is a plant used for nutri-
tional and medicinal purposes, commonly found in tropical
and subtropical regions such as South America [10–12].
In Brazil, it is popularly known as picão-preto [13] and all
parts of the B. pilosa, including its aerial components and/or
roots, are widely used [11]. It is traditionally used as a
diuretic, anti-rheumatic and antidiabetic agent. However,
its anti-inﬂammatory properties raised interest to treat
inﬂammatory gastrointestinal diseases [10,12,14,15].
Gastric antisecretory/antiulcer [16,17], hepatoprotec-
tive [18,19], antihyperglycemic [20], immunomodulatory,
anti-inﬂammatory [21,22] and antitumor [23,24] activi-
ties of B. pilosa have been scientiﬁcally demonstrated. In
addition, antibacterial [25], antihypertensive [26], chemo-
preventive [27], antimalarial [28,29] and antioxidant
[10,24,30] properties have also been reported.
Phytochemistry analysis of this plant has demon-
strated a variety of compounds, which justiﬁes its
wide pharmacological properties and uses [23]. Aliphatic
hydrocarbon derivatives, simple aromatic hydrocarbons,
phenylpropanoid groups, sesquiterpenes, phytosterols,
chalcones and terpenes have been isolated, but polyacety-
lene and ﬂavonoids are considered the main metabolites in
B. pilosa [11,16,19,22,26–31].
There is no doubt about the need to develop ther-
apeutic strategies in order to preventing and treating
mucositis. In this context, the association of a new phar-
macologically active material (B. pilosa extracts) with a
mucoadhesive platform could further improve the man-
agement of chemotherapy-induced mucositis.
Mucoadhesion is deﬁned as the attachment of a macro-
molecule to the mucus layer. The oral administration of
mucoadhesive formulations may  improve the efﬁcacy of
topical treatments and increase drug absorption, since
mucoadhesion can prolong the residence time of the
dosage form in the disease absorption site [32]. Mucoad-
hesive systems for oral administration have been proposed
for the treatment of several disorders such as colitis and
mucositis [33–36]. There are few reports in the literature on
the treatment of chemotherapy-induced intestinal mucosi-
tis with mucoadhesive dosage forms [33,34]. Bioadhesioneports 2 (2015) 563–573
can be obtained through non-speciﬁc interactions between
the mucoadhesive polymer and the mucus (mucoadhe-
sion) or through the speciﬁc interaction of a ligant to
a speciﬁc site at the cellular surface [37]. Polymers that
non-speciﬁcally bind to the mucosa can provide simulta-
neous treatment of the mucositis wounds in the buccal,
stomach and intestinal sites, which can all be affected
by chemotherapy at the same time. Poloxamer 407 is a
thermoreversible non-speciﬁc mucoadhesive copolymer
consisting of ethylene oxide (EO) and propylene oxide
(PO) blocks (EOx–POy–EOx). It also exhibits solubilization
properties improving the apparent solubility of poorly
water-soluble drugs, and is used in various pharmaceutical
applications [38].
In this study, B. pilosa glycolic extract (BPE) was incorpo-
rated in a liquid formulation (BPF) based on poloxamer and
used to prevent the toxic effects induced by chemotherapy
using an in vivo model of 5-FU-induced mucositis.
2. Materials and methods
2.1. Chemicals
Ecobidens® (B. pilosa glycolic extract, BPE) and buty-
lated hydroxytoluene were obtained from Chemyunion
(Sorocaba, SP, Brazil) and Mapric (São Paulo, SP, Brazil),
respectively. Polyethylene glycol l400, propylene glycol
and sodium azide were acquired from Labsynth (Diadema,
SP, Brazil). 5-Fluorouracil, hexadecyltrimethylammonium
bromide, poloxamer 407, bovine serum albumin (BSA),
n-butanol and ortho-dianisidine were purchased from
Sigma–Aldrich (St. Louis, MO,  USA). ImmunoCruzTM mouse
ABC staining systems (sc-2017 and 2018), monoclonal
mouse anti-mouse p53 (clone 3H2820) and polyclonal rab-
bit anti-mouse Bax (clone P-19) antibodies were acquired
from Santa Cruz Biotechnology (CA, USA), whereas 3,3
diaminobenzidine (DAB), Duet strept ABC complex/HRP
kit 0492 and anti-human Bcl-2 (clone 124) antibodies
were obtained from Dako (Carpinteria, CA, USA). Anti-
human ki-67 (clone MM1)  antibodies were acquired from
Novocastra (Newcastle, UK). Trichloroacetic acid, hydro-
gen peroxide (H2O2), tris, hydrochloricacid (HCl), methanol
and xylene were obtained from Vetec (Rio de Janeiro, RJ,
Brazil). Thiobarbituric acid, hematoxylin and eosin stain-
ing were acquired from Merck (Darmstadt, HE, Germany).
Xylazine and ketamine were purchased from Syntec (Cotia,
SP, Brazil) and König (Santana de Parnaíba, SP, Brazil),
respectively.
2.2. Mucoadhesive formulation based on polaxamer
containing B. pilosa (BPF)
According to the manufacturer’s descriptions, B. pilosa
glycolic extract (BPE) (Ecobidens®, Chemyunion, Brazil) is
comprised of water (54–78%, w/w), glycerol (5–25%, w/w),
B. pilosa extract (10–25%, w/w), benzyl alcohol (0.5–1%,
w/w)  and potassium sorbate (0.3–0.8%, w/w). BPE, which
does not have mucoadhesive properties, was used as the
active pharmaceutical ingredient for the preparation of the
BPF, as described below.
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BPF was prepared by mixing polyethylene glycol 400
nd propilenglycol (1:1, v/v) in a heated reactor (65–70 ◦C).
hen 15% (w/v) poloxamer 407 was added to the mixture
nder mechanical stirring until completely dispersed. After
hat, BPE was added to the organic phase and the pH of
he ﬁnal preparation was adjusted with 0.1 M citric acid
pH 6.5). BPF was then placed in an amber ﬂask and stored
nder refrigeration (4◦ C) until use. A blank mucoadhesive
ormulation (control) was prepared as described above, but
he BPE was replaced by a mixture of puriﬁed water and
lycerin (75:25, v/v).
The total polyphenol content of the BPE was  eval-
ated by the Folin Ciocalteau method, as described by
wain and Hillis [39] and modiﬁed by Roesler et al. [40].
otal polyphenols were 88.2 ppm, which was within the
ange (20–200 ppm) of the analysis certiﬁcate issued by the
cobidens® manufacturers.
.3. Animals
The experiments were carried out on male Swiss mice
age: 7–8 weeks; weight: 35–40 g) obtained from the Bio-
erium at the Federal University of Goiás. All efforts were
ealized to ensure the welfare of mice. In this sense, loss
f body weight, food/water consumption and changes in
ctivity and behavior of the animals were monitored daily
s a clinical indication of animal suffering to determine
hen the animals should be humanely sacriﬁced in accor-
ance with Hubrecht and Kirkwood [41]. The animals were
cclimatized for a week prior to beginning the experiments
nd kept under constant environmental conditions with
ight–dark cycles and controlled temperature, while water
nd food were provided ad libitum. The Research Ethics
ommittee of the University approved the experimental
rotocol (UFG 036/2012). At the end of each experi-
ent, the mice were anesthetized with xylazine (10 mg/kg)
nd ketamine hydrochloride (100 mg/kg) administered
ntraperitoneally and euthanized by cervical dislocation
41].
.4. Experimental design
Intestinal mucositis was induced by the intraperitoneal
dministration of 200 mg/kg 5-FU (0.5 mL/animal) diluted
n sterile water, as described by Wu et al. [42]. Mice
ere treated orally (gavage) with doses of BPF or mucoad-
esive formulation without BPE (blank formulation, BF)
0.5 mL/animal) for 6 days, while doses of 5-FU or its vehi-
le were administered on the 4th to 6th days. On the 7th
ay, the animals were euthanized. For body weight and his-
omorphometry analysis, animals (5 mice per group) were
istributed as follows: Group I – Control (blank formula-
ion, BF); Group II – 75 mg/kg BPF; Group III – 100 mg/kg
PF; Group IV – 125 mg/kg BPF; Group V – BF + 5-FU; Group
I – 75 mg/kg BPF + 5-FU; Group VII – 100 mg/kg BPF + 5-
U; Group VIII – 125 mg/kg BPF + 5-FU. For the other assays,
roups I, V and VII were chosen.eports 2 (2015) 563–573 565
2.5. Mice body weight analysis
The animals were weighed daily during the induction
process and treatment of intestinal mucositis. The values
were expressed as the variation in body weight (%) in rela-
tion to the initial weight at the beginning of experiment
[43].
2.6. Intestinal morphometry and histopathological
analysis
The small intestine of each animal was dissected,
washed with a phosphate buffered solution (PBS) and
kept in 10% phosphate buffered formalin (pH 7.4) for his-
tomorphometry evaluation. Intestinal macroscopic cross-
sections were obtained, dehydrated in graded ethanol
(70–100%), cleared in xylene and parafﬁn-embedded.
Parafﬁn-embedded tissue sections of 5 m thickness were
obtained using a microtome (Leica RM 2155, Heidelberg,
BW,  Germany). Following, the slides were dewaxed in
xylene, hydrated using graded ethanol and stained with
hematoxylin and eosin (H&E). Subsequently, ten random
ﬁelds of each slide were photographed using a light micro-
scope (Axio Scope A1 Carl Zeiss, Jena, TH, Germany) at 20×
objective.
During the intestinal morphometry examination, the
intestinal villi, crypts and muscle layer were analyzed using
AxioVision 40 software (Carl Zeiss, Jena, TH, Germany).
The semi-quantitative histopathological examination was
adapted from Wright et al. [44]. The severity of the dam-
age caused by the intestinal mucositis was assessed by ten
different parameters: reduction of the intestinal crypts and
villi; disruptions and abscess formation in the crypts; thick-
ening of the outer muscle layer; integrity of the epithelium
and muscular layer; inﬂammatory cell inﬁltration; vac-
uolization and edema. Scores for each parameter ranging
from 0 to 3 (0 = normal; 1 = mild; 2 = moderate; 3 = severe)
were totaled to reach a histological damage index (HDI)
maximum of 30.
2.7. Immunohistochemistry for detection of Bcl2, Bax,
p53 and Ki-67
Parafﬁn-embedded intestinal sections of 3 m thick-
ness were obtained and mounted on silane-coated
microscope slides. Each slide was deparafﬁnized in xylene,
rehydrated in graded ethanol and washed with tris-
buffered saline (TBS) (pH 7.2–7.4). Antigen retrieval
followed in a citrate buffer (pH 6.0), at 95 ◦C for 20 min.
After that, the slides were cooled to 25 ◦C for 10 min,
washed with TBS and submitted to endogenous perox-
idase blocking in H2O2 (3%) for 30 min. Subsequently,
a nonspeciﬁc protein blocking was  done using bovine
serum albumin (BSA) (1%) at room temperature for 20 min.
The slides were afterwards incubated at 4 ◦C overnight
with one of the following primary monoclonal antibod-
ies: anti-human Ki-67 (at 1:100), anti-human Bcl-2 (at
1:50), anti-mouse p53 (at 1:50), and anti-mouse Bax
(at 1:50). After incubation, the materials were washed
with TBS. Incubation with secondary antibodies followed,
in accordance with the manufacturer’s instructions of
icology Reports 2 (2015) 563–573
Fig. 1. Mice body weight analysis in 5-FU-induced intestinal mucositis
and  its treatment with BPF. The BPF doses (75, 100 or 125 mg/kg) or blank
formulation were administered orally (gavage) to mice over 6 days, while
doses of 5-FU (200 mg/kg) or sterile water were administered intraperi-
toneally from 4th to 6th day. The mice were weighed throughout the 7
days of the experiment to obtain the variation of corporal mass (%). Each
point presents mean ± SD of ﬁve animals (ap < 0.0001 vs. control and BPF
groups (6th and 7th days); bp < 0.001 (6th day) and p < 0.0001 (7th day)
vs.  control and BPF groups; cp < 0.05 (6th day) and p < 0.0001 (7th day) vs.566 P.H.M. de Ávila et al. / Tox
ImmunoCruzTM mouse ABC staining systems sc-2017 and
2018 (Santa Cruz, CA, USA) or Duet strept ABC complex/HRP
kit 0492 (Dako, Carpinteria, CA, USA). Antibody binding was
visualized through the incubation with 3.3 diaminoben-
zidine (DAB) for 7 min, followed by counterstaining with
Mayer’s hematoxylin. The assays were carried out in trip-
licate. Negative controls were obtained by omitting the
primary antibody, which was replaced by 1% PBS–BSA.
The slides were analyzed and photographed using a
light microscope at 20× objective. About 100 epithe-
lial cells of the small intestine were counted in ten
consecutive ﬁelds to determine the percentage of cells
expressing Bcl2, Bax and p53, all antingens involved in the
apoptotic process, and Ki-67, an indicator of cell prolifera-
tion.
2.8. Preparation of intestinal tissue homogenates
A small intestinal segment of each animal was  removed
and stored at −20 ◦C for subsequent analysis. After thaw-
ing the samples, 250 mg  of each intestine were washed in
phosphate buffer (pH 6.0) and transferred to tubes after
which 5 mL  of hexadecyltrimethylammonium bromide
buffer (0.5%, w/v) (pH 6.0) were added to each intesti-
nal fragment. Subsequently, the tissues were homogenized
using Ultra-turrax® T 25 digital (IKA, BW,  Germany) at
10,000 rpm for 5 min. Posteriorly, the samples were cen-
trifuged at 2000 rpm, 4 ◦C for 15 min. The supernatants
obtained were used for assays. The experiments were car-
ried out in triplicate.
2.9. Myeloperoxidase (MPO) activity
A 10 L volume of supernatant from each tissue was
mixed with 200 L of phosphate buffer containing H2O2
(0.1%, v/v) and ortho-dianisidine (1.3%, w/v). After 10 min
incubation at room temperature (25 ◦C), the reaction was
halted by adding 50 L sodium azide (1.3%, w/v). The
optical density reading was performed using a spectropho-
tometer (Thermo Scientiﬁc Multiskan® Spectrum, Boston,
MA,  USA) at 450 nm.
2.10. Malondialdehyde (MDA) activity
About 250 L of the supernatant were homogenized
with 25 L of butylated hydroxytoluene (4%, v/v) in
methanol. Subsequently, 1 mL  of trichloroacetic acid (12%,
w/v), 1 mL  of thiobarbituric acid (0.73%, w/v, in 0.05 M
NaOH) and 750 L of tris/HCl buffer (pH 7.2) were added
to the initial mixture and this was followed by incubation
in a water bath (100 ◦C) for 60 min. After that, the sam-
ples were placed in a vessel containing ice to block the
reaction. A 1.5 mL  volume of n-butanol was added to each
tube followed by homogenization and centrifugation at
5000 rpm, 25 ◦C for 10 min. Then optical density reading of
the supernatants was performed using a spectrophotome-
ter at 532 and 453 nm.  MDA  concentrations were obtained
by subtracting 20% of the absorbance at 453 nm from the
absorbance at 532 nm,  using a molar extinction coefﬁcient
of 1.56 × 105 M−1 cm−1.5-FU; dp < 0.05 (6th day) vs. 5-FU. Two-way ANOVA and Bonferroni test,
p  < 0.05).
2.11. Statistical analysis
The data were expressed as mean ± standard devia-
tion. The inter group variation was  measured by the one-
or two-way Analysis of Variance (ANOVA) followed by
the Bonferroni test using a GraphPad Prism version 5.01
software for Windows (San Diego, CA, USA). A p < 0.05 was
considered to indicate signiﬁcant differences.
3. Results
3.1. Effect of BPF on body weight using 5-FU-induced
intestinal mucositis in mice
As shown in Fig. 1, control groups with no 5-FU, gained
body weight throughout the experimental period, reach-
ing peak weight gains of 10.5 and 8.5%, respectively, on the
7th day. In contrast, animals only treated with 5-FU pre-
sented a signiﬁcant weight loss of 5% on the 6th day and
14.5% on the 7th day of evaluation (p < 0.0001), when com-
pared to controls. When these animals were treated with
BPF, the lowest dose (75 mg/kg) did not show any satis-
factory effect on mouse body weight. On the other hand,
treatment with BPF doses of 100 and 125 mg/kg resulted
in a signiﬁcant gain in body weight of 2 and 4% (p < 0.001),
respectively, on the 6th day, as compared to the control
group. On the 7th day, these groups showed weight losses
of 3.2 and 5.4%, which was  signiﬁcantly lower (p < 0.05)
than in the 5-FU group, especially in mice treated with the
BPF dose of 100 mg/kg (p < 0.0001).
3.2. Effect of BPF on the small intestinal morphometry in
5-FU-induced intestinal mucositis in mice
Morphometric evaluation showed that mice with-
out mucositis and treated with BPF doses (75, 100 and
125 mg/kg) presented no changes in the length of their villi,
crypts or muscle layers as compared to the control group
(Figs. 2A–C). On the other hand, intestinal villi length in
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Fig. 2. Effect of BPF on the villus (A), crypt (B) and muscle layer (C) morphometry of the small intestine in 5-FU-induced intestinal mucositis in mice. The
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only exposed to 5-FU showed severe disruption of crypts,PF  doses (75, 100 or 125 mg/kg) or blank formulation were administere
ater were administered intraperitoneally from 4th to 6th day. On day 7
nimal was collected for morphometry analysis (***p < 0.0001 vs. control 
onferroni test, p < 0.05).
nimals only exposed to 5-FU showed a marked reduction
54%), when compared with the control groups (p < 0.0001).
oreover, this reduction in intestinal villi length was
ower in the animals treated with BPF (p < 0.0001) (30% for
5 mg/kg, 23% for 100 mg/kg and 25% for 125 mg/kg BPF),
hen compared to 5-FU group (Fig. 2A). In relation to the
rypts, the 5-FU group also showed a signiﬁcant decrease
p < 0.0001) of approximately 43.2%, in relation to the con-
rol group (Fig. 2B). Animals with mucositis also showed a
igniﬁcant reduction (p < 0.0001) in the muscular layer. The
reatment of mice with BPF protected against the decrease
n muscle layer triggered by the 5-FU, increasing the mus-
le layer in 17% for 75 mg/kg, 8.6% for 100 mg/kg and 7.6%
or 125 mg/kg (Fig. 2C).Morphometric evaluation was also performed in the
mall intestine tissue of the mucositis-bearing mice treated
ith BPE, in comparison with BPF. Although the treatment (gavage) to mice over 6 days, while doses of 5-FU (200 mg/kg) or sterile
mals (5 mice per group) were euthanized and the small intestine of each
 groups; #p < 0.05 and ###p < 0.0001 vs. 5-FU group. One-way ANOVA and
with BPE showed protective effects against the damage
produced by 5-FU, the plant extract alone did not man-
age to protect against changes in the length of the villi,
crypts or muscle layer as found in the group treated with
the mucoadhesive formulation (data not shown).
3.3. Effect of BPF on the small intestinal histology in
5-FU-induced intestinal mucositis in mice
Mice without mucositis treated with different doses
of BPF showed no signiﬁcant histopathological changes
(data not shown) in the HDI values similar to those
found in the control group (Fig. 3F). However, animalsedema, inﬂammatory inﬁltrate, thinning of the muscular
layer and vacuolization in the intestinal tissue (Fig. 3B),
when compared to animals control (Fig. 3A), with an HDI
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Fig. 3. Effect of BPF on small intestinal histological damage in 5-FU-induced intestinal mucositis in mice. The BPF doses (75, 100 or 125 mg/kg, representative
ﬁgures (C), (D), and (E), respectively) or blank formulation (representative (A)) were administered orally (gavage) to mice over 6 days, while doses of 5-FU
eritone
is and d
erroni te(200  mg/kg, representative (B)) or sterile water were administered intrap
euthanized and the small intestine of each animal was  collected for analys
and  BPF groups; ###p < 0.0001 vs. 5-FU group. One-way ANOVA and Bonf
average of 21.4 (p < 0.0001) (Fig. 3F). This value was approx-
imately 386.4% greater than the control group. In contrast,
the BPF treatment protected against these histopathologi-
cal changes (Fig. 3C–E). Moreover, the groups treated with
75, 100 or 125 mg/kg BPF presented an HDI average of
16.1, 12.5 and 13.6, respectively (Fig. 3F), representing
an increase of 266% for 75 mg/kg, 184.1% for 100 mg/kg
and 209.1% for 125 mg/kg BPF. In view of these results,
associated with body weight and morphometric data, the
treatment of mice with the BPF dose of 100 mg/mL  was
chosen for the subsequent assays.
3.4. Effect of BPF on the expression of Ki-67 in
5-FU-induced intestinal mucositis in mice
The proliferative activity of BPF in 5-FU-induced intesti-
nal mucositis in mice was evaluated through the expression
of Ki-67 by immunohistochemistry. As expected, the
control group showed high cytoplasmic and nuclear
expression of Ki-67 in the villi and crypts, while the
mice treated with only 5-FU demonstrated a reduction
(p < 0.001) of 70.8%. On the other hand, the BPF led to the
restoration of intestinal proliferative activity, since Ki-67
levels were similar to those found in the control group
(Fig. 4).
3.5. Effect of BPF on the expression of Bcl2, Bax and p53
in 5-FU-induced intestinal mucositis in miceThe results of the expressions of Bcl2, Bax and p53
apoptosis markers in 5-FU-induced intestinal mucositis in
mice, as well as their treatments with BPF, evaluated byally from 4th to 6th day. On day 7, the animals (5 mice per group) were
etermination of histological damage index (HDI) (***p < 0.0001 vs. control
st, p < 0.05). Symbol represent:  – inﬂammatory inﬁltrate.
immunohistochemistry, are shown in Fig. 5. These proteins
were predominatly expressed in the inﬂamatory inﬁltrate
of the villi and crypts, with a predominance of nuclear
staining for p53 and cytoplasmic staining for the other
two  markers. The 5-FU led to a signiﬁcant increase in Bax,
as compared to the control group (p < 0.0001). The Bcl2
expression was  reduced along with increased expression
of p53, but with no statistic signiﬁcance. The increase of
Bax and p53 levels was 777.4 and 35% associated with
the decrease of Bcl2 levels of 66%, in comparison to the
control group. In contrast, the expression of Bax in mice
treated with BPF was similar to that of the control group
and statistically signiﬁcant (p < 0.0001) when compared to
5-FU group and. In addition, Bcl2 and p53 levels were also
reduced, although not by statistically signiﬁcant levels.
3.6. Effect of BPF on intestinal MPO and MDA activities in
5-FU-induced intestinal mucositis in mice
MPO  and MDA  activities in the 5-FU group showed sta-
tistically signiﬁcant differences (p < 0.0001), as compared
to the control group, and reached an increase of 188 and
179.2%, respectively. However, the BPF100 + 5-FU group
demonstrated similar MPO  and MDA  activities in rela-
tion to the control group and was  statistically signiﬁcant
(p < 0.0001) in relation to 5-FU group, which obtained a
decrease of 61.7 and 70.6% for MPO  and MDA  activities,
respectively (Fig. 6).4. Discussion
The pathogenesis of intestinal mucositis due to
chemo/radiotherapy is not yet fully understood. Studies
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Fig. 4. Effect of BPF on the expression of Ki-67 cell proliferation indicator in 5-FU-induced intestinal mucositis. The dose of 100 mg/kg BPF or blank
formulation was administered orally (gavage) to mice over 6 days, while doses of 5-FU (200 mg/kg) or sterile water were administered intraperitoneally
from  4th to 6th day. On day 7, the animals (5 mice per group) were euthanized and the small intestine of each animal was collected for detection of Ki-67
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ave reported a reduction in intestinal cell proliferation
ssociated with an increasing rate of apoptosis, which in
urn led to a loss of intestinal arrangement and function,
ainly through villus shortening and crypt destruction.
imilar ﬁndings were reported in this study and by other
uthors [45,46]. Additionally, a focus of edema, inﬂam-
atory inﬁltrate and vacuolization caused by 5-FU which
eached a high histological damage index were demon-
trated here. Simultaneously, a marked body weight loss
as observed, since chemotherapy decreases food intake
nd the inﬂammatory response causes the loss of the nutri-
nt absorption capacity in the small intestine, thereby
esulting in diarrhea, an important dose limiting toxicity
n cancer treatment [47,48].
By contrast, the BPF formulation prevented intestinal
issue injury and loss of body weight, mainly with the
ose of 100 mg/kg in mice with 5-FU-induced intestinal
ucositis. Similar results were obtained in the treatment
f mice with the interleukin 1 receptor antagonist (IL-
Ra) [42]. In addition, interesting results for the treatment
f mucositis have been reported using natural products,
uch as glycoglycerolipids extracted from spinach [49] and
berogast® [44]. Iberogast® is a herbal formula comprising
ine plant extracts used in the treatment of gastrointesti-
al disorders, and although it protects against mucositis,
his phytomedicine does not manage to prevent weight loss
44].
Our preliminary ﬁndings showed the beneﬁcial effect
f B. pilosa glycolic extract (BPE) on intestinal tissue
tructure in 5-FU treated mice (data not shown). Thei-67 (**p < 0.001 vs. control; ##p < 0.001 vs. 5-FU group. One-way ANOVA
incorporation of this plant extract in a mucoadhesive for-
mulation (BPF) has signiﬁcantly improved the effects of
BPE. This could be explained by the more intimate contact
of the plant active principles with the damaged mucosa
over an extended period. Moreover, poloxamer 407 does
not only have mucoadhesive properties [38]. Dumortier
et al. [38] reviewed its pharmaceutical applications and
reported several studies, in which poloxamer has improved
both the cellular and humoral immune response. Thus,
the beneﬁcial effects of BPF could result from the anti-
inﬂammatory effects of the plant active extracts associated
with the mucoadhesive properties of the poloxamer 407.
Regarding to the histomorphometric evaluation, ani-
mals with mucositis and treated with BPF showed a
reorganization of their intestinal structure framework.
Similar results were obtained in other studies which
used an E COG 133 apolipoprotein, a mimetic peptide
[5]; minocycline, a semi-synthetic derivative of tetracy-
cline [50]; and chemokine (C-X-C motif) ligand 9 (CXCL9),
a molecule produced by interferon- stimulated mono-
nuclear cells [2]. However, the magnitude of the in vivo
results presented here, and the simplicity and low cost of
the BPF make this formulation more attractive than syn-
thetic or biological products. It is also worth mentioning
that in vivo toxicological studies reported that B. pilosa
extracts showed no sign of toxicity, corroborating with our
ﬁndings [51–53]. The data obtained in our study regarding
the effects of BPF on normal mice showed that BPF doses
did not lead to body mass loss or changes in the intestinal
histology of healthy mice.
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Fig. 5. Effect of BPF on the expression of Bcl2, Bax and p53 apoptosis markers in 5-FU-induced intestinal mucositis. The dose of 100 mg/kg BPF or blank
formulation (BF) was administered orally (gavage) to mice over 6 days, while doses of 5-FU (200 mg/kg) or sterile water was administered intraperitoneally
from  4th to 6th day. On day 7, the animals (5 mice per group) were euthanized and the small intestine of each animal was collected for detection of Bcl2,
Bax,  p53 by immunohistochemistry. The images are a representation of the expression of these apoptotic markers (***p < 0.0001 vs. control; ###p < 0.0001
vs.  5-FU group. Two-way ANOVA and Bonferroni test, p < 0.05).
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Fig. 6. Effect of BPF on intestinal MPO  (A) and MDA  (B) activity in 5-FU-induced intestinal mucositis in mice. The dose of 100 mg/kg BPF or blank formulation
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In order to clarify the protective mechanisms of BPF in
he intestinal injury triggered by 5-FU, an evaluation was
ade of the expression of apoptotic markers of the Bcl2
amily, which consists of pro-apoptotic and anti-apoptotic
embers such as Bax and Bcl2, respectively [54,55]. Thus,
t was observed that the treatment with the dose of
00 mg/kg BPF led to a reduction in the imbalance between
he rates of expression of Bax and Bcl2. So the BPF would
ppear to modulate the expression of anti-apoptotic mem-
ers at the expense of apoptotic members, and thereby
revent intestinal cell apoptosis. An overexpression of Bax
n association with an underexpression of Bcl2 leads to
poptosis in the affected cells [56,57]. This event is a pro-
ective mechanism used by cells to regulate proliferation,
hich occurs at a reduced rate in a healthy small intestine
1]. In pathological conditions, such as intestinal mucosi-
is, this process is induced mainly by IL-1, which changes
he expression of genes of the Bcl2 family [58,59]. Addi-
ionally, it has been suggested that DNA damage-induced
L-1 secretion may  promote an inﬂammatory cascade via
F-B-independent mechanism in the intestinal mucositis
60].
The treatment with the BPF also reduced the expression
f p53. This stress-induced pro-apoptotic protein is a major
eterminant of the side effects of chemotherapy, since it
s a transcriptional activator of certain pro-apoptotic Bcl2
amily proteins, including Bax. It increases transcription
f the Fas death receptor gene and inhibits the secre-
ion of growth factors [1,59,61]. Thus, as observed in this
tudy, it seems likely that inhibition of apoptotic response
riggered by p53 can effectively reduce intestinal dam-
ge.
Concurrently, it was seen that the intestinal tissue of
nimals which only received doses of 5-FU showed a
arked reduction in the Ki-67 protein nuclear expression.
ontrary data were noted when BPF was administrated, as
he nuclear expression of Ki-67 was increased, a fact indica-
ive of proliferative activity [62]. Therefore, these data once
gain support the protective role of BPF against the intesti-
al mucositis induced by chemotherapy./kg) or sterile water were administered intraperitoneally from 4th to 6th
ine of each animal was collected for MPO  and MDA  analysis. (***p < 0.0001
< 0.05).
In view of the known anti-inﬂammatory and antioxi-
dant role of the BPF, and its effect on the regulation of lipid
peroxidation and inﬂammatory inﬁltration in the intestinal
mucositis, MDA  and MPO  levels were evaluated. MPO  is an
enzyme involved in inﬂammatory processes and is mainly
present in neutrophils. When released in the injured tissue,
it leads to the overproduction of reactive oxygen species
(ROS), which results in the peroxidation of cell membranes
and causes the release of MDA  as a product of this oxidative
process [63,64]. Some studies have reported the involve-
ment of these stress markers in chemotherapy-induced
intestinal mucositis [5,43,44,65–67], corroborating the
data obtained here since the BPF treatment decreased
inﬂammatory inﬁltrate and, consequently, prevented lipid
peroxidation. Similar results have been demonstrated
using grape seed extract [65], apolipoprotein E COG 133
[5], melatonin [67] and proanthocyanidin [66], a natural
antioxidant extracted from Vitis venifera.
The protective activity of B. pilosa has been investigated
and correlated with its antioxidant potential. Yang et al.
[68] demonstrated that this plant protects human eryth-
rocytes against peroxyl radical-induced oxidative damage
in vitro through the reduction of lipid peroxidation and
the increase of cellular antioxidants and ATP levels. Addi-
tionally, Yuan et al. [19] showed that doses of 50 and
100 mg/kg of B. pilosa extract effectively reduced the car-
bon tetrachloride-induced liver damage. This effect was
associated with decreased hepatic transaminases and MDA
content, the restoration of superoxide dismutase and glu-
tathione peroxidase levels and the signiﬁcant inhibition
of NF-B activation. Another study has shown, in vitro or
in mouse skin, that ethyl caffeate, a phenolic compound
isolated from B. pilosa,  also suppressed the activation of
NF-B and its downstream inﬂammatory mediators, such
as iNOS, COX-2 and PGE2 [39], which supports the use of B.
pilosa in inﬂammatory disorders such as intestinal mucosi-
tis.
Given the above, this study demonstrated that the
BPF was shown to be safe and efﬁcient against 5-FU-
induced intestinal mucositis in mice, corroborating with
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the popular use of B. pilosa as an anti-inﬂammatory
agent for gastrointestinal disorders. These results showed
the involvement of Ki-67, MPO, and MDA  in the anti-
inﬂammatory response modulated by the BPF is associated
with its ability to regulate Bax, Bcl2 and p53 apoptotic
markers. More studies are underway to further character-
ize the mechanisms involved in the protective effects of
BPF in order to make it a clinical tool for the prevention
and treatment of intestinal injury in patients undergoing
chemotherapy.
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